Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

The present protocol describes a method for intranasal administration of α-synuclein aggregates. This method provides insights into α-synuclein propagation from the olfactory mucosa to the olfactory bulb in Parkinson's disease.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the presence of Lewy bodies, which are aggregates of α-synuclein (α-Syn). Recently, the disease was proposed to develop and progress through the prion-like propagation of α-Syn aggregates from the olfactory bulb (OB) or dorsal nucleus of the vagus nerve. Although the origin of α-Syn aggregates in the OB remains unclear, their propagation from the olfactory mucosa has been recently suggested. We previously showed that intranasal administration of α-Syn aggregates in a mouse model induced α-Syn pathology in the OB of mice. In this study, we present a method of intranasal administration of α-Syn aggregates that induced α-Syn pathology in the OB of mice. Intranasal administration of α-Syn aggregates is a very simple and straightforward method, and we believe it will be a useful tool in the research for elucidating the origin of α-Syn pathology in the OB and the pathway of α-Syn propagation through the olfactory system.

Introduction

Parkinson's disease (PD), which is characterized by motor symptoms such as bradykinesia, resting tremors, and muscle rigidity, is the second most common neurodegenerative disorder1. PD also presents non-motor symptoms, including olfactory dysfunction, cognitive impairment, depression, hallucinations, constipation, and orthostatic hypotension. Its pathological hallmarks are the dopaminergic cell death in the substantia nigra and the presence of α-synuclein (α-Syn) aggregates, called Lewy bodies2.

Of note, α-Syn is a 140-amino acid protein that exists in the form of a soluble ....

Protocol

C57BL/6J male mice 2 months old were used for this study. All experimental procedures were performed according to national guidelines. The Animal Research Committee of Kyoto University granted ethical approval and permission for this study (MedKyo 23,544).

1. Intranasal administration of α-Syn preformed fibrils

  1. Prepare mouse α-Syn fibrils solution in PBS (4 mg/mL) according to previously reported methods11. Wrap the tube with a tra.......

Representative Results

Figure 3 shows several examples of α-Syn aggregates in the OB. In the present study, we administered α-Syn aggregates into the unilateral nostril. The two nasal cavities are separated by the nasal septum, and each OB projects the olfactory sensory neurons to each nasal cavity separately. Therefore, the OB on the contralateral side can be used as a control.

P-α-Syn pathology was not observed in the OB on the treated side after 1 and 3 months (

Discussion

In a previous study, the administration of α-Syn aggregates into the nasal cavity of macaques induced the death of dopaminergic cells and iron deposition in the substantia nigra, although α-Syn aggregates were not observed21. Daily administration of A53T human α-Syn aggregates into the nasal cavity of prion promoter α-Syn transgenic mice (M83 mice) for 28 days was reported to induce α-Syn pathology in the brains and motor symptoms in mice19,

Acknowledgements

All experiments were supported by Rie Hikawa. We extend our thanks to Yasuko Matsuzawa for the paperwork. This study was supported by JSPS KAKENHI (M.S., No. JP19K23779, JP20K16493, and JP20H00663).

....

Materials

NameCompanyCatalog NumberComments
All-in-One Fluorescence Microscope BZ-X710KEYENCEN/AAll-in-One microscope
Ampicillin Sodium SaltNacalai tesque02739-32
Bioruptor IISonicbioBR2006AWater bath type sonicator.
Butorphanol tartrateMeiji Seika PharmaWAK-52850
Cellulose tubeMISUMIUC20-32-100
DeepWellMaximizerTAITECMBR-022UPShaker
DynaCompetent Cells Zip BL21(DE3)BioDynamics Laboratory Inc.DS255Competent cell
EntellanSigma-Aldrich107961Rapid mounting medium for microscopy
Graefe Extra Fine Forceps Curved SerratedFST11152-10 forceps
Hardened Fine ScissorsFST14090-09scissors
Histofine Simple stain mouse MAX-PO (R)Nichirei Bioscience414341Universal Immuno-peroxidase Polymer, anti-Rabbit
ImageJ ver 1.52pNANAhttps://imagej.net/
innova4200New Brunswick scientific9105085Incubator shaker
Isopropyl-β-D-thiogalactopyranosideNacalai tesque19742-94
LB broth, LennoxNacalai tesque20066-24
Leica EG 1150 HLeica14 0388 86 108Modular Tissue Embedding Center
Leica TP 1020Leica14 0422 85108Automatic Tissue Processor 
MedetomidineFuji Film135-17473
Microm HM325 Rotary MicrotomeThermo Scientific902100
MidazolamMaruishi Seiyaku4987-211-76210-0
New hematoxylin Type GMuto65-9197-38Hematoxylin solution
Normal winged needle for vein D type, 25GTERUMONN2332R25G needle
Optima TLX UltracentrifugeBeckman Couler8043-30-1197Ultracentrifuge
P10 pipetteGilsonFA10002P
ParaffinLeica39601095
paraformaldehydeNacalai tesque30525-89-4
Peroxidase Stain DAB KitNacalai tesque25985-50
Pirece BCA Protein Assay KitsThermo Scientific23225BCA assay
pRK172Addgene#134504Plasmid
Q-Sepharose Fast Flow. cytiva17051001Ion exchange resin

References

  1. Tysnes, O. B., Storstein, A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 124 (8), 901-905 (2017).
  2. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nature Rev Neurosci. 2, 492-501 (2001).

Explore More Articles

Neuroscience

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved